$PYXS Cashflow Statement | Understand Stock

$PYXS

$1.84 +$0.15 (8.88%) Close

$PYXS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Non-cash research and development expenses
Non-cash operating lease expense
Non-cash loss from equity method investment in joint venture
Changes in fair value of derivative liability
Impairment of in-process research and development intangible asset
Accretion of discount on marketable debt securities
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities
Deferred revenues
Deferred tax liabilities
Other

Net cash used in operating activities
Investing activities
Cash acquired in acquisition of Apexigen, Inc.
Redemption of marketable debt securities
Purchase of marketable debt securities
Purchase of property and equipment
Investment in joint venture
Net cash provided by (used in) investing activities

Financing activities
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs
Proceeds from issuance of common stock pursuant to ATM program, net of offering costs
Tax withholding payments related to net settlement of restricted common stock
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs
Proceeds from issuance of common stock in initial public offering, net of issuance costs
Proceeds from the exercise of stock options
Proceeds from the sale of stock under employee stock purchase plan
Proceeds from issuance of common stock under ESPP
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental cash flow information:
Cash paid for interest
Cash paid for taxes
Cash paid for income taxes
Noncash investing and financing activities
ROU asset in exchange for financing lease liability
Shares, warrants, and replacement stock options and restricted stock units issued for acquisition of Apexigen, Inc.
Property and equipment in accounts payable and accrued expenses
Operating lease right-of-use assets obtained in exchange for operating lease liabilities
Issuance of common stock to Pfizer Inc.

Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents and restricted cash shown in the statement of cash flows

Comments